IFW

I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313, on 04 August 2004.

M. Bud Nelson
*Name*
*Signature*
04 August 2004
*Date of Signature*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: John Dwyer & Mary K. Delmedico

Application No. 10/671,316 Examiner:

Filed: 24 September 2003 Art Unit

For: Method for production of antivirals by use of HIV-derived HR1 peptides, trimers formed therefrom

Commissioner for Patents
Alexandria, VA

**Docket No. TRM-002**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**
**37 CFR 1.56 and 1.97(b)(3)**

Applicants wish to make of record the following reference under the provisions of 37 CFR 1.56 and 1.97(b)(3) **and** to provide a copy of relevant background with respect to the application. The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application, or is to be considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove any document as a cited reference against the claims of the present invention.

References Cited

Please see attached Form PTO-1449 for list of publications, legible copies of all publication listed are enclosed.

Statement of Relevancy

Non Patent Literature Documents

1. Lu et al. (*J. Virol.* 2001 75:11146-11156); and Liu et al. (*Biochemistry* 2001 40:2797-2807) disclose gp41 ectodomain proteins (N-terminal peptide-linker-C-terminal peptide) each with an amino acid substitution (alanine- Lu et al.; threonine- Liu et al.) in the N-terminal portion of the gp41 ectodomain protein.

2. Eckert and Kim (*PNAS* 2001 98:11187-11192) discloses GCN4-HIV N-terminal peptide fusion proteins.

3. Ferrer et al. (*Nat. Struct. Biol.* 1999 6:953-960) discloses screening with a GCN4-HIV N-terminal peptide fusion protein.

Respectfully submitted,

M. Bud Nelson
Reg. No. 35,300
Attorney for the Applicants

# INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*



| Docket Number (Optional) | Application Number |
|---|---|
| TRM-002 | 10/671,316 |
| **Applicant(s)** | |
| Dwyer & Delmedico | |
| **Filing Date** | **Group Art Unit** |
| 09/24/2003 | |

## U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

## U.S. PATENT APPLICATION PUBLICATIONS

| *EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

## FOREIGN PATENT DOCUMENTS

| | REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | Translation YES | Translation NO |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

## OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

| | | |
|---|---|---|
| | | Liu et al., "Structural and Functional Analysis of the HIV gp41 Core Containing an Ile573 to Thr Substitution..." Biochemistry, 2001, 40:2797-2807. |
| | | Lu et al., "Structural and Functional Analysis of Interhelical Interactions of the Human Immunodeficiency Virus Type 1 gp 41 Envelope...."; J. Virology, 2001, 75:11146-11156. |
| | | Eckert & Kim, "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region"; PNAS, 2001, 98:11187-11192. |
| | | Ferrer et al., "Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries...."; Nature Structural Biology, 1999, 6:953-960. |

| EXAMINER | DATE CONSIDERED |
|---|---|
| | |

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.